Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis
Hepatology International - 2019
Tóm tắt
l-Asparaginase is a bacterial enzyme used in the treatment of acute lymphoblastic leukemia. In the ongoing U.S. Drug-Induced Liver Injury Network (DILIN) prospective study, standard and pegylated asparaginase were the most frequent cause of liver injury with jaundice among anti-cancer agents (8 of 40: 20%). The unique features of this hepatotoxicity are described. Eight cases from 5 DILIN centers were reviewed for clinical course, laboratory values, imaging, and histopathology. Seven females, aged 29–59 years, and one 8-year-old boy, all with leukemia, developed jaundice within 9–21 days (median 15 days) of starting asparaginase or pegaspargase, during the first (n = 6) or second (n = 2) cycle. Prominent symptoms were jaundice (n = 8), fatigue (6), abdominal pain (6) but rarely pruritus (1). Initial median ALT level was 284 U/L (range 83–1076), Alk P 159 U/L (64–452), and bilirubin 4.4 mg/dL (3.7–8.4). Bilirubin levels rose thereafter in all patients to median peak of 17.5 mg/dL (11.7–25.7), INR rose to 1.1–1.7 and serum albumin fell to 1.5–2.6 g/dL. Hepatic imaging revealed fatty liver in all patients. Liver biopsy showed steatosis but minimal hepatocyte necrosis. One patient restarted on pegaspargase re-developed less severe injury. Asparaginase is a common cause of antineoplastic-induced liver injury with jaundice, typically with short latency, marked steatosis, and prolonged jaundice, which can lead to delays in antileukemic therapy. The cause of injury is likely direct inhibition of hepatic protein synthesis caused by asparagine depletion.
Từ khóa
Tài liệu tham khảo
Egler RA, Ahuja SP, Matloub Y. l-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother 2016;7:62–71
Raetz EA, Salzer WL. Tolerability and efficacy of l-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2010;32:554–563
Horowitz B, Madras BK, Meister A, et al. Asparagine synthetase activity of mouse leukemias. Science 1968;160:533–535
Broome JD. Studies on the mechanism of tumor inhibition by l-asparaginase. Effects of the enzyme on asparagine levels in the blood, normal tissues, and 6C3HED lymphomas of mice: differences in asparagine formation and utilization in asparaginase-sensitive and -resistant lymphoma cells. J Exp Med 1968;127:1055–1072
Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2009;7:600–606
Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. Coli l-asparaginase in man. Cancer 1970;25(2):253–278
Zubrod CG. The clinical toxicities of l-asparaginase: in treatment of leukemia and lymphoma. Pediatrics 1970;45:555–559
Cairo MS. Adverse reactions of l-asparaginase. Am J Pediatr Hematol Oncol 1982;4:335–339
Hijiya N, van der Sluis IM. Asparaginase-associated toxicity in children with acute lympholastic leukemia. Leuk Lymphoma 2016;57:748–757
Horvat TZ, Pecoraro JJ, Daley RJ, et al. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance. Leuk Res 2016;50:17–20
Chalasani N, Bonkovsky HL, Fontana R, et al. United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 2015;148:1340–1352
Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009;32:55–68
Rockey DC, Seeff LB, Rochon J, et al. US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010;51:2117–2126
Karnes JH, Shaffer CM, Bastarache L, et al. Comparison of HLA allelic imputation programs. PLoS One 2017;12:30172444
Gragert L, Fingerson S, Albrecht M, et al. Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations. Blood 2014;124:2657–2665
Urayama KY, Thompson PD, Taylor M, et al. Genetic variation in the extended major histocompatibility complex and susceptibility to childhood acute lymphoblastic leukemia: a review of the evidence. Font Oncol 2013;3:300
Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211–1218
Burke PW, Aldoss I, Lunning MA, et al. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses. Leuk Res 2018;66:49–56
Pratt CB, Johnson WW. Duration and severity of fatty metamorphosis of the liver following l-asparaginase therapy. Cancer 1971;28:361–364
Sahoo S, Hart J. Histopathological features of l-asparaginase-induced liver disease. Seminar Liver Dis 2003;23:295–299
Webber BL, Freiman I. The liver in kwashiorkor. A clinical and electron microscopic study. Arch Pathol 1974;98:400–408
Roesmann A, Afify M, Panse J, et al. l-carnitine ameliorates l-asparaginase-induced acute liver toxicity in steatotic rat livers. Chemotherapy 2013;59:167–175
Alshiekh-Nasany R, Douer D. l-carnitine for treatment of pegaspargase-induced hepatotoxicity. Acta Haematol 2016;135:208–210.
Al-Nawakil C, Willems L, Mauprivez C, et al. Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors. Leuk Lymphoma 2014;55:1670–1674
Blackman A, Boutin A, Shimanovsky A, et al. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: a case report and review of the literature. J Oncol Pharm Pract 2018;24:393–397
Jenkins R, Perlin E. Severe hepatotoxicity from Escherichia coli l-asparaginase. J Natl Med Assoc 1987;79(775):779
Bodmer M, Sulz M, Stadlmann S. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with l-asparaginase. Digestion 2006;74:28–32
Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol 2016;96:375–380
Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma 2011;52:2237–2253